trending Market Intelligence /marketintelligence/en/news-insights/trending/ATaUugWPSy1x2yvb64Ilkg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aurinia to raise $166.7M via common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aurinia to raise $166.7M via common stock offering

Aurinia Pharmaceuticals Inc. priced a public offering of its common stock to raise about $166.7 million in gross proceeds.

The Canadian biotechnology company is offering 11,115,165 shares for $15 each. Underwriters will also be given a 30-day option to buy up to an additional 1,667,274 shares from the company.

The offering is expected to close by Dec. 12. Jefferies LLC and SVB Leerink LLC are joint book-running managers, and H.C. Wainwright & Co. LLC, Oppenheimer & Co. Inc. and Bloom Burton Securities Inc. are the co-managers for the offering.

The Victoria, British Columbia-based company plans to use the net proceeds from the offering primarily to prepare for upcoming commercialization and launch activities. Aurinia recently reported positive results for its medicine voclosporin, and plans to seek U.S. regulatory approval for the drug during the first half of 2020.